DOCSLIB.ORG

The Hydrolysis of Inositol Phospholipid in Mouse Exocrine Pancreas

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Hydrolysis of Inositol Phospholipid in Mouse Exocrine Pancreas THE HYDROLYSIS OF INOSITOL PHOSPHOLIPID IN IVIOUSE EXOCRINE PANCREAS ,,r'ir:::'r]. *. DEGREE OF DOCTOR OF PHILOSOPHY of The Department of Physiology Uni vers i ty of Adel ai de , South Austra'l i a by KARIN ANNE TENNES B.Sc.(Hons.) 1984 fi.6sx'-eL,'( I ? - S" 8:'" TABLE OF CONTENTS Page SUMMARY . (v.ii) DECLARATI0N (x) AC KNOI,ILEDGEMENTS (xi ) LIST OF TABLES (xii) LIST 0F FIGURES (xiv) CHAPTER 1 : INTRODUCTION 2 CHAPTER 2 LITERATURE REVIEI^, I 2.t PANCRIATIC STRUCTURE AND FUNCTION 9 2.2 INTERACTION BETI^IEEN ENDOCRINE AND EXOCRINE PANCREAS 23 2.3 PANCREATIC SECRETAGOGUES 27 2.3 (a) Secretagogues which Increase the Intra- cel I ul ar Concentrati on of Cal ci um 27 2.3 (b) Secretagogues wh'ich Cause an Increase in the Intracel I ul ar Concentrati on of cAl'lP 28 2.3 (c) Pancreatic Secretagogues which do not Appear to Act via Increas'ing the Intra- cellular Concentration of Calcium or cAMP 42 2.4 THE ROLE OF CALCIUM IN PANCREATIC ENZYIrIE SECRETION 47 2.a G) Evidence for the Involvement of Calcium in Pancreatic Enzyme Secretion 47 2.4 (b) Evidence for the Involvement of Changes i n l,lembrane Potenti al i n Protei n Secreti on 49 2.a (c) Cytop'lasmic Calcium Concentrations in Pancreatic Acinar Cells 56 ( j ) (i i ) Page 2.5 CALCIUM FLUXES IN PANCREATIC ACINAR CELLS : THE EVENTS LEADING TO INCREASID INTRACELLULAR CALCIUM CON CENTRATI ON 60 2.6 THE RELATIONSHIP BETI^IEEN INHIBITION OF PROTEIN SECRETION, CYTOSOLIC CALCIUM CONCENTRATION AND RECEPTOR OCCUPATION IN THE EXOCRINE PANCREAS 70 2.7 CALCIUM-ACTIVATED STIMULUS-SECRETION COUPLING IN EXOCRINE PANCREAS 76 2.7 (a) Protein Kinase C and Pancreatic Exocrine Secreti on 77 2.7 (6) Calcium-activated, Calmoduì'in-dependent Protein Kinase and Pancreatic Exocrine Secreti on B5 2.8 : PHOSPHATIDYLINOSITOL : THI INITIAL DISCOVERY 88 2.9 : "PTDINS EFFECT" 1953-1980 90 2.9 (a) Phosphatidylinositol Metabolism 91 2.9 (b) The Subcellular Distribution of Phosphol i pase C 95 2.9 (c) Activation and l4odulation of Ptdlns- speci fi c Phosphol i pase C 97 2.9 (d) The Calcium-Dependency of Phospholipase C Acti vi ty 99 2.I0 z "PTDINS EFFECT" 1981-1984 101 2.10(a) Po'lyphosphoinosi tide : Metabolism t02 2.10(b) Po'lyphosphoinositide Phosphodiesterase : Activation and Modulation 106 Z.tt : SITE OF INOSITOL PHOSPHOLIPID METABOLISM 110 2.12 : MEASUREMENT OF THE AGONIST.STIMULATED HYDROLYSIS OF INOSITOL PHOSPHOLIPID 119 (iii) lgge 2.T3 : THE CALCIUM DEPENDENCY OF INOSITOL PHOSPHOLIPID METABOLISM IN EXOCRINE PANCREAS L32 2.I4 z THE ROLE 0F IN0SITOL PH0SPHOLIPID HYDR0LYSIS IN MEDIATING STIMULATION OF THE CELL RESPONSE 140 2.1a(a) The Role of Inosi tol Phosphol ipid Hydrolysi s i n Mobi I i zi ng Cal ci um 141 2.I4(b) The Role of Inositol Phospho'lipid Hydroìysìs in Activation of Protein Kinase C 153 2.T5 : THE RELATIONSHIP BETWEEN INOSITOL PHOSPHOLIPID HYDROLYSIS AND RECEPTOR OCCUPATION 154 2.16 : INOSITOL PHOSPHOLIPID METABOLISM AND CYCLIC AMP 158 2.t7 : LITERATURE REVI EI^i : CONCLUSION 161 CHAPTER 3 MATERIALS AND METHODS t62 3.1 EXPERIMENTAL ANI¡IALS 163 3.2 I4EASUREMENT OF THE HYDROLYSIS OF INOSITOL PHOSPHOL IP ID 163 3.2 (a) Assay Procedure 163 3.2 (b) Radioactive Counting 165 3.3 EXTRACTION AND CHROI4ATOGRAPHIC SEPARATION OF PHOSPH 0L I P I DS LAB E LLED in uiuo hIITH nty o - Q-e g'1 INOS I TOL 165 3.4 EXTRACTION AND CHROMATOGRAPHIC SEPARATION OF 3H. LABELLTD COMPOUNDS RELEASED FR}M mso-(2-3H) INOSITOL- LABELLED INOSITOL PHOSPHOLIPID 166 3.5 : INDUCTION OF DIABETES AND MAINTENANCE OF DIABETIC MICI r67 (iv) !gg-e- 3.5 (a) STZ-induced Diabetes r67 3.5 (b) Blood Glucose Determination 168 3.5 (c) Insulin Maintenance of Diabetic Mice 169 3.5 (d) Inositol Phospholipid Hydrolysis in Diabetic Mice T7L 3.6 : DISSOCIATI0N 0F PANCREATIC ACINAR CELLS 173 3.7 : AMYLASE SECRETI0N 174 3.7 (a) Amy'lase Secretion in Pancreatic Sl'ices 174 3.7 (b) Amyìase Secretion in Pancreatic Acini 176 3.8 DETERMINATION OF ADENOSINE TRIPHOSPHATE (ATP) CONTENT 177 3.9 : SOLUTIONS AND CHEI{ICALS L7B 3.9 (a) Solutions 178 3.9 (b) Chemicals 181 (i ) Radiochemicals 181 (i i ) Chemicals I82 3.10 : STATISTICS 184 CHAPTER 4 VALIDATION OF THE METHOD DEVELOPED TO MEASURE THE HYDROLYSIS OF INOSITOL PHOSPHOLIPID IN MOUSE EXOCRINE PANCREAS 186 4.1 INTRODUCTION t87 4.2 MATERIALS AND I{ETHODS 191 4.3 RESULTS t92 4.4 D ISCUSS ION 2I0 CHAPTER 5 INVESTIGATION OF INOSITOL PHOSPHOLIPID HYDROLYSIS AS AN EARLY EVENT IN ACTIVATION OF THE EXOCRINE PANCREAS 217 (v) Page 5.1 INTRODUCTI ON 218 5.2 MATERIALS AND METHODS 22I 5.3 RESULTS 225 5.4 DISCUSS I ON 242 CHAPTER 6 : THE ROLE OF CALCIUM IN THE HYDROLYSIS OF INOSITOL PHOSPHOLIPID IN EXOCRINE PANCREAS 25r 6.1 INTRODUCTION 252 6.2 MATERIALS AND METHODS 256 6.2 (a) Inositol Phospho'lipid Hydro'lys'is and Intracel I ul ar Ca2+ 257 6.2 (b) Inositol Phospholipid Hydrolysis and Extracellular Ca2+ 26L 6.3 : RESULTS 262 6.3 (a) Inositol Phospholipid Hydroìysis and Intracellular Ca2+ 263 6.3 (b) Inositol Phospholipid Hydrolysis and Potentiation by Ca2+ 280 6.4 DISCUSS ION 296 6.4 (a) The Effect of Lanthanum in Agonist- stimulated Tissue 313 6.4 (b) The Effect of Lanthanum in Unstimulated Ti ssue 316 6.a (c) The Effect of l4anganese in Agonist- stimulated Tissue 317 6.4 (d) The Effect of Manganese in Unstimulated Ti ssue 318 (vi ) Page 6.4 (e) Concluding Summary 319 (i) The site associated with potentiation of basal breakdown 319 (ii) The site associated with potentiation of agonist-stimulated breakdown 319 CHAPTER 7 THE RELATIONSHIP BETI^JEEN THE HYDROLYSIS OF INOSITOL PHOSPHOLIPID AND THE SECRETION OF AMYLASE IN MOUSE EXOCRINE PANCREAS 324 7.L INTRODUCTION 325 7.2 : MATERIALS AND METHODS 326 7.3 RESULTS 328 7.4 DISCUSSION 337 CHAPTER 8 CONCLUSION 345 8.1 CONCLUDING DISCUSSION 345 BIBLIOGRAPHY 358 SUMMARY 1 A nethod was developed which allows the rapid, reproducible measurement of the hydrolysis of inositol phospho'lipid in mouse exocrine pancreas. The technique involves the in uiuolabelling of pancreati c ti ssue wi th rnao -(2-3 H) i nos'i to] and does not requi re the time-consum'ing extraction and chromatographic separation of 'l'ip'ids which has been necessary in the majority of assays of phos phoi nos i ti de turnover. The measurement of the release of myo-(2-3H) inositol-labelled products from inositol phospholìpid provides a direct assay of phosphoinosi t'ide breakdown and not of a combinati on of hydro'lysis and resynthesis, since the (3H)-inositol released is not re- incorporated into inositol phospholipid. In addition, the increase in (3H)-'inos'itol released is not due to agonist-act'ivat'ion of the phosphatidyìinositol : rn7o-inositol exchange enzyme which would cause a complication in measuring lipid breakdown due to an increase in exchange of inositol between lip'id-bound and free states. Since the method measures the ('tt)-inositol-label'led products of phosphoinositide breakdown the vaìidity of the method does not depend on whether the I i pi d hydro'lysed i s phosphati dy'l i nosi to'l , phosphatidyl inositol-4 phosphate or phosphatidylinositol-4,5 bi sphosphate. This assay facilitates the study of inositol phospholipid hydrolysis. In particular, an improved examination of the dose-dependent (vi i ) (vìii) relationship between'lipid hydro'lys'is and pancreatìc function is poss i b'le . 2 The agonist-stimulated breakdown of inositol phospholipid was found to be closeìy linked to receptor activation. This lipid response is not dependent on the agon'ist-activated influx of Na+ and does not requ'ire an intact cytoske'leta'l network or protein synthes'is. A dependency of the agonist-stimulated lipid breakdown on ATp was identified, which supported the proposal that phosphatidy'linositol- 4,5 bisphosphate and not phosphat'idyìinositol may be the initial lìpid hydro'lysed folìowing receptor activation. 3 The agonìst-stimulated breakdown of inositol phospholipid ìs not Ca2+-dependent since 'it occurs in the absence of extracellular Ca2+ and does not require the release of Ca2+ from intracellular stores. Inositol lipid breakdown is not activated by ca2+ since an increase in intracellular ca2+ with ionophore A23r87 does not stimulate the tipid response. 4 The presence of Ca2+ in the extracelìular medium potentiates inositol phospho'lipid hydroìysis. This potentiation ìs not due to the movement of Ca2+ through the plasma membrane since neomycin, an agent which blocks Ca2+ influx, does not alter the potentiation effect. 5 Two sites of potentiation by Ca2+ of inositol ìipid hydrolysis have been identified on the external surface of the pancreat'ic cell membrane. One site is associated with potentiation of unstimulated (ix) inositol lipid hydrolysis. This site is lanthanum insensitive but manganese can replace Ca2+ at this site. The second site is associated with potentiation of agonist-stimulated inositol ìipid hydroìys'is. Lanthanum and manganese compete with Ca2+ at this site to remove the potentiation effect. 6 Results show that at h'igh concentrations of agonists the degree of inositol phospholipid hydrolys'is correlates with the degree of inhibition of amylase secretion. Since this effect on secretion is due to Ca2+ the result suggests that inositol lipid breakdown and the increase in intracellular Ca2+ are correlated. 7 At low concentrations of agonists, when amyìase secretion is stimulated, the degree of inositol 'lipid hydrolysis is very small but may be sufficient to cause release of Ca2+ from intracelìular s tores .
Load more

Recommended publications
  • Amylase Release from Rat Parotid Gland Slices C.L
    Br. J. P!harmnic. (1981) 73, 517-523 THE EFFECTS OF SUBSTANCE P AND RELATED PEPTIDES ON a- AMYLASE RELEASE FROM RAT PAROTID GLAND SLICES C.L. BROWN & M.R. HANLEY MRC Neurochemical Pharmacology Unit, Medical Research Council Centre, Medical School, Hills Road, Cambridge CB2 2QH 1 The effects of substance P and related peptides on amylase release from rat parotid gland slices have been investigated. 2 Supramaximal concentrations (1 F.M) of substance P caused enhancement of amylase release over the basal level within 1 min; this lasted for at least 40 min at 30°C. 3 Substance P-stimulated amylase release was partially dependent on extracellular calcium and could be inhibited by 50% upon removal of extracellular calcium. 4 Substance P stimulated amylase release in a dose-dependent manner with an ED50 of 18 nm. 5 All C-terminal fragments of substance P were less potent than substance P in stimulating amylase release. The C-terminal hexapeptide of substance P was the minimum structure for potent activity in this system, having 1/3 to 1/8 the potency of substance P. There was a dramatic drop in potency for the C-terminal pentapeptide of substance P or substance P free acid. Physalaemin was more potent than substance P (ED50 = 7 nM), eledoisin was about equipotent with substance P (ED5o = 17 nM), and kassinin less potent than substance P (ED50 = 150 nM). 6 The structure-activity profile observed is very similar to that for stimulation of salivation in vivo, indicating that the same receptors are involved in mediating these responses.
    [Show full text]
  • Intracerebroventricular Responses to Neuropeptide Y in the Antagonists
    British Journal of Pharmacology (1996) 117, 241-249 B 1996 Stockton Press All rights reserved 0007-1188/96 $12.00 9 Intracerebroventricular responses to neuropeptide y in the conscious rat: characterization of its receptor with selective antagonists Pierre Picard & 'Rejean Couture Department of Physiology, Faculty of Medicine, Universite de Montreal, C.P. 6128, Succursale Centre-Ville, Montreal, Quebec, Canada H3C 3J7 1 The cardiovascular and behavioural effects elicited by the intracerebroventricular (i.c.v.) administration of neuropeptide y (NPy) in the conscious rat were assessed before and 5 min after i.c.v. pretreatment with antagonists selective for NKI (RP 67,580), NK2 (SR 48,968) and NK3 (R 820) receptors. In addition, the central effects of NPy before and after desensitization of the NK, and NK2 receptors with high doses of substance P (SP) and neurokinin A (NKA) were compared. 2 Intracerebroventricular injection of NPy (10-780 pmol) evoked dose- and time-dependent increases in mean arterial blood pressure (MAP), heart rate (HR), face washing, head scratching, grooming and wet-dog shake behaviours. Similar injection of vehicle or 1 pmol NPy had no significant effect on those parameters. 3 The cardiovascular and behavioural responses elicited by NPy (25 pmol) were significantly and dose- dependently reduced by pretreatment with 650 pmol and 6.5 nmol of SR 48,968. No inhibition of NPy responses was observed when 6.5 nmol of RP 67,580 was used in a similar study. Moreover, the prior co-administration of SR 48,968 (6.5 nmol) and RP 67,580 (6.5 nmol) with or without R 820 (6.5 nmol) did not reduce further the central effects of NPy and significant residual responses (30-50%) remained.
    [Show full text]
  • Back Matter (PDF)
    MOLECULAR PHARMACOLOGY 26:605-609 AUTHOR INDEX FOR VOLUME 26 A berg, Aaron, Watanabe, Kyoichi A., Fox, Jack J., and Philips, Frederick S. Metabolic Competition Studies of 2’-Fluoro-S-iodo-l- Albengres, Edith. See Urien, Riant, Brioude, and Tillement, 322 f3-D-arabinofuranosylcytosine in Vero Cells and Herpes Simplex Albuquerque, E. X. See Aracava, Ikeda, Daly, and Brooks, 304 Type 1-Infected Vero Cells, 587 See Ikeda, Aronstam, Daly, and Aracava, 293 Christie, Nelwyn T. See Cantoni, Swann, Drath, and Costa, 360 Ambler, S. Kelly, Brown, R. Dale, and Taylor, Palmer. The Chrivia, John. See Bolger, Dionne, Johnson, and Taylor, 57 Relationship between Phosphatidylinositol Metabolism and Mobili- Colacino, Joseph M. See Chou, Lopez, Feinberg, Watanabe, Fox, and zation of Intracellular Calcium Elicited by Alpha,-Adrenergic Recep- Philips, 587 tar Stimulation in BC3H-1 Muscle Cells, 405 Collins, Sheila, and Marletta, Michael A. Carcinogen-Binding Aracava, Y. Ikeda, S. R., Daly, J. W., Brookes, N., and Albu- Proteins: High-Affinity Binding Sites for Benzo[ajpyrene in Mouse querque, E. X. Interactions of Bupivacaine with Ionic Channels of Liver Distinct from the Ah Receptor, 353 the Nicotonic Receptor: Analysis of Single-Channel Currents, 304 Cooper, Dermot M. F. See Sadler and Mailer, 526 See Ikeda, Aronstam, Daly, and Albuquerque, 293 Corbett, Michael D. See Doerge, 348 Aronstam, R. S. See Ikeda, S. R. , Daly, J. W., Aracava, Y. , and Cormier, Ethel. See Jordan, Lieberman, Koch, Bagley, and Ruenitz, Albuquerque, E. X. , 293 272 Aub, Debra L. See Putney, McKinney, and Leslie, 261 Costa, Erminio. See Quach, Tang, Kageyama, Mocchetti, Guidotti, Meek, and Schwartz, 255 B Costa, Max.
    [Show full text]
  • The Vanilloid Receptor and Hypertension1
    Acta Pharmacologica Sinica 2005 Mar; 26 (3): 286–294 Invited review The vanilloid receptor and hypertension1 Donna H WANG2 Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, MI 48825, USA Key words Abstract TRP family; afferent neurons; capsaicin; Mammalian transient receptor potential (TRP) channels consist of six related pro- calcitonin gene-related peptide; substance P; tein sub-families that are involved in a variety of pathophysiological function, and vanilloid receptor; renin-angiotensin- aldosterone system; endothelin, sympathetic disease development. The TRPV1 channel, a member of the TRPV sub-family, is nervous system; salt-sensitive hypertension identified by expression cloning using the “hot” pepper-derived vanilloid com- pound capsaicin as a ligand. Therefore, TRPV1 is also referred as the vanilloid 1 This work was supported in part by National receptor (VR1) or the capsaicin receptor. VR1 is mainly expressed in a subpopula- Institutes of Health (grants HL-52279 and tion of primary afferent neurons that project to cardiovascular and renal tissues. HL-57853) and a grant from the Michigan These capsaicin-sensitive primary afferent neurons are not only involved in the Economic Development Corporation. 2 Correspondence to Donna H WANG, MD. perception of somatic and visceral pain, but also have a “sensory-effector” function. Phn 1-517-432-0797. Regarding the latter, these neurons release stored neuropeptides through a cal- Fax 1-517-432-1326. cium-dependent mechanism via the binding of capsaicin to VR1. The most studied E-mail [email protected] sensory neuropeptides are calcitonin gene-related peptide (CGRP) and substance Received 2004-08-10 P (SP), which are potent vasodilators and natriuretic/diuretic factors.
    [Show full text]
  • And Substance P and Dumping SEIKI ITO, YOICHI IWASAKI, TAKESHI
    Tohoku J. exp. Med., 1981, 135, 11-21 Neurotensin and Substance P and Dumping Syndrome SEIKI ITO, YOICHI IWASAKI,TAKESHI MOMOTSU, KATSUMI TAKAI,AKIRA SHIBATA, YOICHI MATSUBARA* and TERUKAZU MUTO* The First Department of Internal Medicine and * the First Department of Surgery, Niigata University School of Medicine, Niigata 95.E ITO, S., IWASAKI, Y., MOMOTSU, T., TAKAI, K., SHIBATA, A., MATSUBARA, Y, and MUTO, T. Neurotensin and Substance P and Dumping Syndrome. Tohoku J. exp. Med., 1981, 135 (1), 11-21 To investigste the pathophysiologi- cal relation between releases of gut hormones and dumping syndrome, plasma radioimmunoassayable neurotesin, substance P, glucagon-like immunoreactivity (GLI), insulin and blood sugar were measured in both gastrectomized patients and control subjects after 50 g oral glucose tolerance tests. Remarkable rises of radioimmunoassayable neurotesin and GLI were found in all gastrectomized patients, but not in control subjects. In contrast, plasma radioimmunoassayable substance P responses were not detected in either gastrectomized patients or control subjects. There were three patients with symptoms of dumping syndrome in the early stage of the test. Plasma radioimmunoassayable neurotensin responses in two out of these three were higher than those in other patients, though the other patient with symptoms had the same degree of neurotensin elevation as patients with no symptoms. In view of the pharmacological effects of neurotensin, it could not be ruled out that a part of the early symptoms of dumping syndrome
    [Show full text]
  • Effect of Bradykinin and Eledoisin on Renal Function in the Dog Department of Internal Medicine (Prof. T. Torikai), Tohoku Unive
    Tohoku J. exp. Med., 1966, 89, 69-76 Effect of Bradykinin and Eledoisin on Renal Function in the Dog Takashi Furuyama,. Chikara Suzuki, Hiroshi Saito, Yozo Onozawa , Ryuji Shioji, Shozo Rikimaru, Keishi Abe and Kaoru Yoshinaga Department of Internal Medicine (Prof. T. Torikai), Tohoku University School of Medicine, Sendai Bradykinin (0.05, 0.1 and 0.2 ƒÊg/kg/min) and eledoisin (0.5, 1.0, 5.0 and 10.0ng/kg/min) were infused directly into the left renal artery of anesthetized dogs to demonstrate the effects of these peptides on renal function. Urinary volume, endogenous creatinine clearance (GFR), PAR clearance (RPF) and excretion of electrolytes were increased by infusion of these two peptides, but no constant change was observed in UK/U ,Va ratio. These data demonstrate that the increase in urinary output and electrolyte excretion is caused by the augmentation of tubular load of solutes which resulted from the increase of RPF and GFR. Tachy phylaxis was observed in dogs which received repeated infusions of bradykinin but this phenomenon was less distinct in the case of eledoisin. Bradykinin is a nonapeptide formed by the action of kinin-forming enzymes upon alpha-2-globulin fraction of the plasma and it plays an important role in the local control of blood flow to certain tissues. On the other hand, eledoisin isolated from the salivary gland of Eledone, is endecapeptide having powerful kinin-like activity2. Bradykinin and eledoisin administered intravenously produce reduction in systemic blood pressure because of vasodilator action of the peptides.2,3 Since the change in systemic blood pressure affects renal function in experiments with intravenous infusion of the peptides, it is difficult to reveal their direct action on the kidney.
    [Show full text]
  • Biologically Active Peptides from Australian Amphibians
    Biologically Active Peptides from Australian Amphibians _________________________________ A thesis submitted for the Degree of Doctor of Philosophy by Rebecca Jo Jackway B. Sc. (Biomed.) (Hons.) from the Department of Chemistry, The University of Adelaide August, 2008 Chapter 6 Amphibian Neuropeptides 6.1 Introduction 6.1.1 Amphibian Neuropeptides The identification and characterisation of neuropeptides in amphibians has provided invaluable understanding of not only amphibian ecology and physiology but also of mammalian physiology. In the 1960’s Erspamer demonstrated that a variety of the peptides isolated from amphibian skin secretions were homologous to mammalian neurotransmitters and hormones (reviewed in [10]). Erspamer postulated that every amphibian neuropeptide would have a mammalian counterpart and as a result several were subsequently identified. For example, the discovery of amphibian bombesins lead to their identification in the GI tract and brain of mammals [394]. Neuropeptides form an integral part of an animal’s defence and can assist in regulation of dermal physiology. Neuropeptides can be defined as peptidergic neurotransmitters that are produced by neurons, and can influence the immune response [395], display activities in the CNS and have various other endocrine functions [10]. Generally, neuropeptides exert their biological effects through interactions with G protein-coupled receptors distributed throughout the CNS and periphery and can affect varied activities depending on tissue type. As a result, these peptides have biological significance with possible application to medical sciences. Neuropeptides isolated from amphibians will be discussed in this chapter, with emphasis on the investigation into the biological activity of peptides isolated from several Litoria and Crinia species. Many neurotransmitters and hormones active in the CNS are ubiquitous among all vertebrates, however, active neuropeptides from amphibian skin have limited distributions and are unique to a restricted number of species.
    [Show full text]
  • Wo 2009/015286 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 29 January 2009 (29.01.2009) WO 2009/015286 A2 (51) International Patent Classification: Not classified AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (21) International Application Number: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, PCT/US2008/071055 IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, (22) International Filing Date: 24 July 2008 (24.07.2008) MX, MY,MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TJ, (25) Filing Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 60/961,872 24 July 2007 (24.07.2007) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (71) Applicant (for all designated States except US): NEXBIO, European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, INC. [US/US]; 10665 Sorrento Valley Road, San Diego, California 92121 (US). FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, (72) Inventors; and CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • JOHN R. VANE Wellcome Research Laboratories, Langley Court, Beckenham, Kent, U.K
    ADVENTURES AND EXCURSIONS IN BIO- ASSAY: THE STEPPING STONES TO PROSTACYCLIN Nobel lecture, 8 December, 1982 by JOHN R. VANE Wellcome Research Laboratories, Langley Court, Beckenham, Kent, U.K. Physiology has spawned many biological sciences, amongst them my own field of pharmacology. No man has made a more important contribution to the fields of physiology and pharmacology than Sir Henry Dale (1875-1968, Nobel Laureate in Physiology or Medicine in 1936). Dale had a great influence not only on British pharmacology in general but also on my own scientific endea- vours. Indeed, I can put forward a strong case for considering myself as one of Dale’s scientific grandchildren. My early days as a pharmacologist were in- fluenced not only by Dale himself but also by his school of colleagues, including Burn, Gaddum and von Euler. It was Burn who taught me the principles and practice of bioassay. Some of Gaddum’s first publications were on the develop- ment of specific and sensitive methods for biological assay and he maintained a deep interest in this subject for the rest of his life (1). In 1964 he said “the pharmacologist has been a ‘jack of all trades’ borrowing from physiology, biochemistry, pathology, microbiology and statistics – but he has developed one technique of his own, and that is the technique of bioassay” (2). Expensive, powerful and sophisticated chemical methods, such as gas chro- matography and mass spectrometry, have been developed and perfected for detection and quantification of prostaglandins (PGs) and related substances. One should not forget, however, that starting with the discovery and isolation of prostaglandins by von Euler (3; see also Bergstrom in this volume), biologi- cal techniques and bioassay have contributed very substantially to the develop- ment of the field.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov Et Al
    US 2015.0050713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov et al. (43) Pub. Date: Feb. 19, 2015 (54) TECHNOLOGY FOR THE PREPARATION OF Publication Classification MCROPARTICLES (51) Int. Cl. (71) Applicant: Ansun Biopharma, Inc., San Diego, CA CI2N 9/96 (2006.01) (US) CI2N 7/00 (2006.01) CI2N IS/II3 (2006.01) (72) Inventors: Michael P. Malakhov, San Francisco, C07D 305/.4 (2006.01) CA (US); Fang Fang, Rancho Santa Fe, C07K 4/765 (2006.01) CA (US) C07K9/00 (2006.01) (52) U.S. Cl. CPC ................ CI2N 9/96 (2013.01); C07K 14/765 (21) Appl. No.: 14/341,502 (2013.01); C07K9/008 (2013.01): CI2N 15/113 (2013.01); C07D 305/14 (2013.01); (22) Filed: Jul. 25, 2014 CI2N 7/00 (2013.01); C12N 2770/00051 (2013.01) O O USPC ........... 435/188: 530/363; 530/350, 530/367; Related U.S. Application Data 530/385:536/16.8; 536/13.7: 540/336; 530/317; (63) Continuation of application No. 13/874,424, filed on 536/24.5; 530/328; 552/203; 549/510; 435/238 Apr. 30, 2013, now abandoned, which is a continuation (57) ABSTRACT of application No. 13/250,653, filed on Sep. 30, 2011, Mi h duced b tacti lution of a now abandoned, which is a continuation of application 1crospneres are produced by contacting a sol No. 12/179.520, filed on Jul 24, 2008, now aban- macromolecule or small molecule in a solvent with an ant1 doned sa- 1 ws s s Solvent and a counterion, and chilling the solution.
    [Show full text]
  • Neuropeptides in the Human Brainstem
    Investigación Clínica ISSN: 0535-5133 Universidad del Zulia Duque-Díaz, Ewing; Martínez-Rangel, Diana; Ruiz-Roa, Silvia Neuropeptides in the human brainstem Investigación Clínica, vol. 59, no. 2, 2018, April-June, pp. 161-178 Universidad del Zulia DOI: https://doi.org/10.22209/IC.v59n2a06 Available in: https://www.redalyc.org/articulo.oa?id=372960175007 How to cite Complete issue Scientific Information System Redalyc More information about this article Network of Scientific Journals from Latin America and the Caribbean, Spain and Journal's webpage in redalyc.org Portugal Project academic non-profit, developed under the open access initiative Invest Clin 59(2): 161 - 178, 2018 https//doi.org/10.22209/IC.v59n2a06 Neuropeptides in the human brainstem. Ewing Duque-Díaz1, Diana Martínez-Rangel1 and Silvia Ruiz-Roa1,2. 1Universidad de Santander UDES. Laboratory of Neuroscience, School of Medicine, Bucaramanga, Colombia. 2Universidad de Santander UDES. Laboratory of Neuroscience, Nursing Program, Bucaramanga, Colombia. Key words: neuropeptides; mesencephalon; pons; medulla oblongata; human. Abstract. The physiological importance of the brainstem has made it one of the most studied structures of the central nervous system of mammals (in- cluding human). This structure receives somatic and visceral inputs and its neurons send motor efferences by means of the cranial nerves, which innervate the head, neck and sensory organs, and it mediates in several actions such as movement, pain, cardiovascular, respiratory, salivary, sleep, vigil and sexual mechanisms. Most of these actions are mediated by neuroactive substances denominated neuropeptides, which are short amino acid chains widespread dis- tributed in the nervous system, that play a role in neurotransmission, neuro- modulation (paracrine and autocrine actions), and act as neurohormones.
    [Show full text]
  • Prediction of Peptide Retention Times in High-Pressure Liquid Chromatography on the Basis of Amino Acid Composition (Lipophilicity/Separation Techniques) JAMES L
    Proc. Natl. Acad. Sci. USA Vol. 77, No. 3, pp. 1632-1636, March 1980 Medical Sciences Prediction of peptide retention times in high-pressure liquid chromatography on the basis of amino acid composition (lipophilicity/separation techniques) JAMES L. MEEK Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, D.C. 20032 Communicated by Bruce Merrifield, December 17,1979 ABSTRACT Analysis of peptides by reverse-phase high- on octadecylsilyl silica gel is a quite different process from oc- pressure liquid chromatography would be simplified if retention tanol/water partition and from the unavailability of hydro- times could be predicted by summing the contribution to re- groups of the peptides. It is the tention of each of the peptide's amino acid side chains. This phobicity data for terminal paper describes the derivation of values ("retention coeffi- purpose of this paper to show that "retention coefficients" can cients") that represent the contribution to retention of each of be derived directly from HPLC data for all amino acids and the common amino acids and end groups. Peptide retention end groups such that the retention time of a peptide can be times were determined on a Bio-Rad "ODS" column at room predicted from the sum of the retention coefficients for each temperature with a linear gradient from 0.1 M NaCIO4, pH 7.4 amino acid and end group. or 2.1, at 0 min to 60% acetonitrile/0.1 M NaCIO4 at 80 min. The NaClO4, a chaotropic agent, was added to improve peak shape and to minimize conformational effects.
    [Show full text]